Sudarshan Pharma Industries Ltd

Sudarshan Pharma Industries Ltd has exhibited a notable shift in price momentum, moving from a mildly bearish technical stance to a more sideways trend, reflecting a complex interplay of bullish and bearish signals across key technical indicators. Despite a strong one-month return of 37.5%, the stock’s longer-term performance remains subdued, prompting a cautious outlook from analysts.

Sudarshan Pharma Industries Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 October 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 February 2026, providing investors with the most recent insights into the company’s performance and outlook.

Sudarshan Pharma Industries Ltd is rated Sell by MarketsMOJO, with this rating last updated on 19 October 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Sudarshan Pharma Industries Ltd has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. Despite a strong weekly price rally, the stock faces mixed signals from key technical indicators, reflecting uncertainty in its near-term trajectory within the Specialty Chemicals sector.

Sudarshan Pharma Industries Ltd has exhibited a notable shift in its technical momentum, moving from a mildly bearish stance to a more sideways trend, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. Despite a strong weekly price surge of 3.43%, the stock’s longer-term performance remains subdued, prompting a detailed analysis of its technical indicators and market context.

Sudarshan Pharma Industries Ltd has witnessed a notable shift in its technical momentum, with price action surging 10.00% in a single day to close at ₹25.41. Despite this sharp uptick, the stock remains under pressure over longer time frames, reflecting a complex interplay of technical indicators and market sentiment within the Specialty Chemicals sector.

Sudarshan Pharma Industries Ltd is rated Sell by MarketsMOJO, with this rating last updated on 19 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 February 2026, providing investors with the latest insights into the company’s performance and outlook.

Sudarshan Pharma Industries Limited reported consolidated net profit of ₹4.36 crores for Q3 FY26, registering growth of 4.31% quarter-on-quarter and 51.39% year-on-year. The specialty chemicals manufacturer, with a market capitalisation of ₹468.32 crores, delivered robust revenue expansion of 45.26% YoY to ₹168.01 crores, though sequential momentum moderated with a marginal decline of 0.51% QoQ. The stock has plunged 54.89% over the past year, significantly underperforming both the Sensex and its sector peers, as investors grapple with concerns over elevated debt levels and compressed profitability metrics despite sustained topline growth.

Sudarshan Pharma Industries Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 October 2025. However, the analysis and financial metrics discussed below reflect the stock's current position as of 24 January 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Sudarshan Pharma Industries Ltd, a key player in the specialty chemicals sector, has experienced a notable shift in price momentum, with technical indicators signalling a bearish trend. The stock’s recent performance, combined with deteriorating moving averages and mixed signals from momentum oscillators, suggests mounting pressure on the share price amid broader market challenges.

Sudarshan Pharma Industries Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 January 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Sudarshan Pharma Industries, a key player in the Specialty Chemicals sector, has exhibited a notable shift in its technical momentum as of late December 2025. The stock’s recent price movements and technical indicators suggest a transition from a bearish stance to a more nuanced mildly bearish outlook, reflecting evolving market dynamics and investor sentiment.

Sudarshan Pharma, a microcap player in the Specialty Chemicals sector, has undergone a revision in its market evaluation metrics, reflecting a nuanced view of its recent financial and technical performance. This shift comes amid a backdrop of mixed signals across key analytical parameters, including quality, valuation, financial trends, and technical outlook.

Sudarshan Pharma Industries, a key player in the specialty chemicals sector, has experienced a notable shift in its technical momentum and market assessment. Recent data reveals changes in key technical indicators including MACD, RSI, moving averages, and Bollinger Bands, reflecting evolving investor sentiment and price dynamics amid broader market conditions.

Sudarshan Pharma Industries, a key player in the Specialty Chemicals sector, has experienced a notable shift in its technical momentum, reflecting changes in market sentiment and price dynamics. Recent evaluation adjustments reveal a transition from a bearish to a mildly bearish technical trend, accompanied by mixed signals from key indicators such as MACD, RSI, and moving averages. This article analyses these developments in the context of the company’s price performance and broader market conditions.

Sudarshan Pharma Industries has experienced a notable shift in its technical momentum, reflecting evolving market dynamics within the specialty chemicals sector. Recent evaluation adjustments reveal a transition from mildly bearish to bearish technical trends, underscoring a complex interplay of price movements and indicator signals that investors should carefully consider.